CVS Health (CVS) Tops Q3 EPS by 33c, Raises FY EPS Guidance

CVS Health (NYSE: CVS) reported Q3 EPS of $1.66, $0.33 better than the analyst estimate of $1.33. Revenue for the quarter came in at $67.1 billion versus the consensus estimate of $66.58 billion.

GUIDANCE:

CVS Health sees FY2020 EPS of $7.35-$7.45, versus the consensus of $7.24.

• The Company raised its full year 2020 GAAP diluted EPS guidance range to $5.60 to $5.70 from $5.16 to $5.29 and its full year 2020 Adjusted EPS guidance range to $7.35 to $7.45 from $7.14 to $7.27. The Company also raised its full year 2020 cash flow from operations guidance range to $12.75 billion to $13.25 billion from $11.0 billion to $11.5 billion. While providing these updates to its full year guidance, the Company continues to acknowledge the inherent and unprecedented uncertainty surrounding the ongoing COVID-19 pandemic and its impact.

For earnings history and earnings-related data on CVS Health (CVS) click here.

You May Also Be Interested In

• RH (RH) Tops Q1 EPS by 12c
• Lands' End (LE) Tops Q1 EPS by 8c ; Offers Guidance
• CVS adds Zepbound back to formulary, expands GLP-1 coverage